Fighting COVID-19
As COVID-19 began to evolve into a global pandemic in 2020, Octapharma created a special project team to confront the disease.
Annual Reports
The Annual Reports provide a comprehensive overview of Octapharma, explaining who we are and what we do, as well as highlighting our progress against our strategic priorities and financial results.
:quality(80)/f/54881/1440x1080/ced7885321/octapharma-annual-report-2020-cover_2.jpg)
Annual Report 2020
Remaining strong, resilient and agile
Family-owned since being established in 1983, Octapharma is a global healthcare company reaching hundreds of thousands of patients every year.
Our passion drives us to provide new health solutions advancing human life. The importance of this is ever more evident this year with the advent of the global pandemic. We continue our mission to help even more people in need through the strength and resilience of all our employees.
Reflecting on a remarkable year
"The COVID-19 global pandemic has re-shaped much of our lives, but I am proud to report that Octapharma has not only risen to every challenge but continued to evolve and grow."
Wolfgang Marguerre
Chairman and Chief Executive Officer of the Octapharma Group
Delivering strong performance in 2020
"We have delivered yet another excellent performance in 2020, with strong sales growth and robust profitability despite the challenges."
Roger Mächler
Chief Financial Officer
The COVID-19 pandemic affected every part of our business, from plasma collection, to our supply chain, production and engagement with key stakeholders.
However, our employees across the business rallied to mitigate the worst effects of the crisis and, through close collaboration and thousands of individual actions, continued to produce and deliver life-saving medications on behalf of tens of thousands of patients who rely on them, while successfully executing on our strategy for profitable organic growth.
More stories
Reaching a community in need
Up to one in 200 children have Paediatric Acute-onset Neuropsychiatric Syndrome (PANS). The medical options to treat this rare disease remain limited but immunomodulation with intravenous immunoglobulin (IVIg) seems to offer a real breakthrough.
Facing the challenge
While so much of the world has stopped for COVID-19, bleeding disorders have not. “Patients with a lifelong bleeding disorder such as VWD cannot put their treatment on “hold”. They rely on their medicines,” explains Kerri.
Patient Blood Management
Over a million cardiac surgical procedures that are performed each year require the transfusion of blood components. Although transfusion can be life-saving, they also carry inherent risks. Approaches, such as a PBM, improves patient safety.
Cancer was not part of the plan
Ingrid has always enjoyed life. “I laugh a lot. I have fun”, she says. In March 2003, she was diagnosed with chronic lymphocytic leukaemia (CLL) – just nine years after her sister died of acute leukaemia.
Download the Octapharma Annual Reports in English, French, German and Spanish, which also contain our complete audited financial statements.